How many insider declarations has Bruns Ingmar filed?

Bruns Ingmar has filed 3 public insider declarations with SEC (Form 4).

What is Bruns Ingmar's role?

Bruns Ingmar's reported role is not specified by the regulator across the filings.

Which companies does Bruns Ingmar report trades for?

Bruns Ingmar reports trades for Zentalis Pharmaceuticals, Inc..

What is Bruns Ingmar's declared buy vs sell volume?

Across the available history, declared buys total 44k€ and disposals 6k€.

← Executives ★ Sign in to follow

BI

Bruns Ingmar

OFFICER

·SEC (Form 4)

Zentalis Pharmaceuticals, Inc.

0

申报总数

0

公司

€43,896

▲ 买入（1 笔）

€6,110

▼ 卖出（1 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

1

T+90 胜率

0%

T+90 平均收益

-51.0%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

Explore the full record of transactions filed by Bruns Ingmar. Insider active across 1 company, notably Zentalis Pharmaceuticals, Inc.. In total, 3 disclosures have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €50k. History available since 3 February 2025. The latest transaction was disclosed on 6 February 2026 (Cession). Regulator: SEC (Form 4). The full history is free.

Companies and markets linked to Bruns Ingmar

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Zentalis Pharmaceuticals, Inc. (US)

申报3 总计

▼

Bruns Ingmar

Chief Medical Officer高管2026年2月6日Zentalis Pharmaceuticals, Inc.

US$7,19733SEC ↗

2,962 股@ US$2.429712.2% 占其流量Common StockSEC:0001838041-26-000004:0

▲

Bruns Ingmar

Chief Medical Officer高管2025年2月6日Zentalis Pharmaceuticals, Inc.

US$45,65641SEC ↗

20,000 股@ US$2.2828100.0% 占其流量Common StockSEC:0001725160-25-000047:0

标准退出：2025年5月7日 (T+90)

◆

Bruns Ingmar

Chief Medical Officer高管2025年2月3日Zentalis Pharmaceuticals, Inc.

0SEC ↗

16,629 股0Common StockSEC:0001725160-25-000037:0

3 条申报中的 3 条

InsidersTradesSigma

← Executives ★ Sign in to follow

BI

Bruns Ingmar

OFFICER

·SEC (Form 4)

Zentalis Pharmaceuticals, Inc.

0

申报总数

0

公司

€43,896

▲ 买入（1 笔）

€6,110

▼ 卖出（1 笔）

内部人交易记录

其他

已披露买入

1

已披露卖出

1

T+90 胜率

0%

T+90 平均收益

-51.0%

基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。

信号历史

Explore the full record of transactions filed by Bruns Ingmar. Insider active across 1 company, notably Zentalis Pharmaceuticals, Inc.. In total, 3 disclosures have been logged. Breakdown: 1 buy · 1 sell. Total volume traded: €50k. History available since 3 February 2025. The latest transaction was disclosed on 6 February 2026 (Cession). Regulator: SEC (Form 4). The full history is free.